New drug combo aims to shrink stomach tumors before surgery
NCT ID NCT07464756
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether adding the drugs SHR-1701 and apatinib to standard chemotherapy before surgery can improve outcomes for people with resectable locally advanced stomach or gastroesophageal junction cancer. About 80 adults will be randomly assigned to receive either SHR-1701 plus chemotherapy or SHR-1701 with apatinib plus chemotherapy before their operation. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a less extensive stomach surgery preserve appetite better?
- New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer
- Breath of life: new test could sniff out gut cancers before they spread
- Drug cocktail aims to shrink Hard-to-Treat stomach cancers